id: injectable_medication_formulation_to_aud_medication_adherence
name: Injectable Extended-Release Naltrexone Formulation â†’ Alcohol Use Disorder Medication
  Adherence
from_node:
  node_id: injectable_medication_formulation
  node_name: Injectable Extended-Release Naltrexone Formulation
to_node:
  node_id: aud_medication_adherence
  node_name: Alcohol Use Disorder Medication Adherence
direction: positive
category: healthcare_access
mechanism_pathway:
- 'Step 1: Injectable formulation eliminates daily dosing burden compared to oral
  medications'
- 'Step 2: Monthly administration reduces opportunity for missed doses and decision
  fatigue'
- 'Step 3: Healthcare system-delivered injections create structural adherence support
  through scheduled appointments'
- 'Step 4: Sustained medication levels from extended-release formulation maintain
  therapeutic coverage'
evidence:
  quality_rating: C
  n_studies: 1
  primary_citation: Hayden Stewart et al. 2021. "Veteran adherence to oral versus
    injectable AUD medication treatment.." *The mental health clinician*. https://doi.org/10.9740/mhc.2021.05.194
last_updated: '2025-12-02'
version: '1.0'
llm_metadata:
  extracted_by: claude-sonnet-4-5-20250929
  extraction_date: '2025-12-02T18:12:06.679337'
  batch_id: msgbatch_01AKnPJgzm7Fk9qubgAz9GaD
moderators:
- name: medication_type_comparison
  direction: strengthens
  strength: strong
  description: XR naltrexone showed significantly higher adherence versus oral naltrexone
    at all time points and versus disulfiram at 3, 6, and 9 months
- name: acamprosate_comparison
  direction: weakens
  strength: moderate
  description: XR naltrexone adherence was not significantly different from acamprosate
    at any time point
_source_file: /Users/mauriceelhelou/Library/CloudStorage/OneDrive-HarvardUniversity/New
  folder (2)/healthsystems/mechanism-bank/mechanisms/healthcare_access/injectable_medication_formulation_to_aud_medication_adherence.yaml
_category: healthcare_access
